Dublin-based drug development company Merrion Pharmaceuticals has announced that has applied for a listing on New York's Nasdaq stock market. It also plans to take a listing on Dublin's IEX market.
Merrion, which was set up in 2004, specialises in developing oral dosage forms of drugs that are difficult to absorb.
In November, Merrion said it had raised €8m in its latest funding round. The main investors included Dr Tony Ryan and company chairman Declan Ryan.
